Discounted Cash Flow (DCF) Analysis Levered

vTv Therapeutics Inc. (VTVT)

$0.8156

+0.00 (+0.10%)
All numbers are in Millions, Currency in USD
Stock DCF: 0.25 | 0.8156 | overvalue

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 12.432.766.410000000
Revenue (%)
Operating Cash Flow -26.86-23.02-18-0.02-0.02-0.01-0.01-0.01-0.01-0.01
Operating Cash Flow (%)
Capital Expenditure -0-0.07-0.08-0-0-0-0-0-0-0
Capital Expenditure (%)
Free Cash Flow -26.86-23.09-18.08-0.02-0.02-0.01-0.01-0.01-0.01-0.01

Weighted Average Cost Of Capital

Share price $ 0.8,156
Beta -1.197
Diluted Shares Outstanding 47.14
Cost of Debt
Tax Rate 22.95
After-tax Cost of Debt 0.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity -1.866
Total Debt 0.72
Total Equity 38.45
Total Capital 39.16
Debt Weighting 1.83
Equity Weighting 98.17
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 12.432.766.410000000
Operating Cash Flow -26.86-23.02-18-0.02-0.02-0.01-0.01-0.01-0.01-0.01
Capital Expenditure -0-0.07-0.08-0-0-0-0-0-0-0
Free Cash Flow -26.86-23.09-18.08-0.02-0.02-0.01-0.01-0.01-0.01-0.01
WACC
PV LFCF -0.02-0.01-0.01-0.01-0.01-0.01
SUM PV LFCF -0.05

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -1.83
Free cash flow (t + 1) -0.01
Terminal Value 0.18
Present Value of Terminal Value 0.20

Intrinsic Value

Enterprise Value 0.15
Net Debt -11.41
Equity Value 11.56
Shares Outstanding 47.14
Equity Value Per Share 0.25